Morphometry of benign prostatic hyperplasia during androgen suppressive therapy: Relationships among epithelial content, PSA density, and clinical outcome

Scandinavian Journal of Urology and Nephrology, Supplement

Volumn 30, Issue 179, 1996, Pages 113-117

  Svindland, Aud ^a   Eri, Lars M ^b   Tveter, Kjell J ^b  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Gonadorelin; Light microscopy; Morphometry; Prostatic hypertrophy

Indexed keywords

ANTIANDROGEN; LEUPRORELIN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MALE; PATHOLOGY; PROSTATE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MORPHOMETRICS; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; BIOPSY; DOUBLE-BLIND METHOD; HUMANS; LEUPROLIDE; MALE; PROSTATE; PROSTATIC HYPERPLASIA;

EID: 0030347586     PISSN: 03008886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter KJ and the Scandinavian BPH Study Group. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995; 46: 631-637.
2. Bartsch G, Müller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979; 122: 487-491.
3. Bluestein DL, Oesterling JE. Hormonal therapy in the management of benign prostatic hyperplasia. In: Lepor H and Lawson RK (Eds) Prostate diseases. Philadelphia, WB Saunders Company,1993, pp.182-198.
4. Deering RE, Bigler SA, King J, Choongkittaworn M, Aramburu E, Brawer MK. Morphometric quantitation of stroma in human benign prostatic hyperplasia. Urology 1994; 44: 64-70.
5. DeKlerk DP, Coffey DS. Quantitative determination of prostatic epithelial and stromal hyperplasia by a new technique. Biomorphometrics. Invest Urol 1978; 16: 240-245.
6. Eri LM, Tveter KJ. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol 1993; 150: 359-364.
7. Hamilton PW, Allen DC. Morphometry in histopathology. Review article. J Pathol 1995; 175: 369-379.
8. Laroque PA, Prahalada S, Molon-Noblot S, Cohen SM, Soper K, Duprat P, Peter CP, vanZwieten MJ. Quantitative evaluation of glandular and stromal departments in hyperplastic dog prostates: Effect of 5-alpha reductase inhibitors. Prostate 1995; 27: 121-128.
9. Lepor H, Wang B, Shapiro E. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels Urology 1994; 44: 199-205.
10. Levine AC, Kirschenbaum A, Kaplan P, Droller MA, Gabrilove JL. Serum prostate-antigen levels in patients with benign prostatic hypertrophy treated with leuprolide. Urology 1989; 34: 10-13.
11. Mandell K, Partin A, Hill G, Epstein J, Stutzman R, Carter HB, Walsh P. PSA density in BPH: Correlations with stromal epithelial ratios and influence of age. J Urol 1993; 149: 448A (abstract 943).
12. Marks LS, Treiger B, Dorey FJ, Fu YS, deKernion JB. Morphometry of the prostate: Distribution of tissue components in hyperplastic glands. J Urol 1994; 151: 380A (abstract 611).
13. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987; 317: 599-604.
14. Robert M, Costa P, Bressolle F, Mottet N, Navratil H. Percentage area density of epithelial and mesenchymal components in benign prostatic hyperplasia: comparison of results between single biopsy, multiple biopsies and multiple tissue specimens. Br J Urol 1995; 75: 317-324.
15. Schröder FH. Medical treatment of benign prostatic hyperplasia: The effect of surgical or medical castration. In: Kurth K, Newling DWW. Benign prostatic hyperplasia. Recent progress in clinical research and practice. EORTC Genitourinary Group monograph 12. New York Wiley-Liss 1994: 191-196.
16. Shapiro E. Prostatic morphogenesis, stromal-epithelial interactions, zonal anatomy, and quantitative morphometry. In: Lepor H and Lawson RK (Eds) Prostate diseases. Philadelphia, WB Saunders Company,1993: 8-16.
17. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297-307.
18. Shapiro S, Lepor H. The relationship between histology and clinical response to alpha blockade in' men with symptomatic BPH. J Urol 1991; 145: 265A (abstract 211).
19. Silver RI, McConnell JD. Androgen suppression therapy for benign prostatic hyperplasia. Current Opinion in Urology 1994; 4: 22-28.
20. Walsh PC. The heterogeneity of benign prostatic hyperplasia. J Urol 1993; 150: 1587.
21. Weber JP, Oesterling JE, Peters CA, Partin AW, Chan DW, Walsh PC. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol 1989; 141: 889-892.